Cellectis (CLLS) Capital Leases (2021 - 2022)
Cellectis (CLLS) posted quarterly Capital Leases of $89000.0 for Q1 2022, down 99.49% quarter-over-quarter from $17.5 million in Q4 2021.
Powered by 
Analysis
Cellectis (CLLS) Capital Leases (2021 - 2022) Analysis & Trends
Cellectis' Capital Leases history runs 2 years deep, the most recent figure standing at $89000.0 for Q1 2022.
- In Q1 2022, Capital Leases changed N/A year-over-year to $89000.0; the TTM figure through Mar 2022 stood at $89000.0 (changed N/A YoY), while the FY2021 annual figure was $17.5 million, changed N/A from the prior year.
- Capital Leases for Q1 2022 stood at $89000.0, down from $17.5 million in the prior quarter.
- The five-year high for Capital Leases was $17.5 million in Q4 2021, with the low at $89000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |